• Who we are
  • CD28 targeting
  • How it works

Krzysztof Masternak

Leadership Team

Krzysztof Masternak, Director of Discovery

After obtaining a PhD in molecular virology at the University of Lausanne, Krzysztof worked for several year on gene expression regulation at the University of Geneva Medical School. He joined Novimmune in 2002, where he led several discovery programs to clinical ready stage.

As head of biology at Novimmune, Krzysztof was responsible for pioneering therapeutic CD47 dual targeting programs on the bispecific antibody platform.

Now as Director of Therapeutic Programs at Light Chain Bioscience, he drives the development of novel bispecific antibodies.

Back

New publication in ImmunoTherapy of Cancer

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies

Read more

LinkedIn